title: Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility.
abstract: The treatment modalities of erectile dysfunction range from oral pharmacotherapy to intracavernosal injections, intraurethral pellets, vacuum erectile devices, and the surgical option of penile prosthesis insertion. Oral phosphodiesterase 5 inhibitors still remain the preferred treatment for patients since they are the least invasive, not to mention that they can be prescribed by non-urologists. Due to these factors, there has been development of newer drugs with fewer side effects. This is a review of the second generation phosphodiesterase 5 inhibitor, avanafil, looking into its pharmacology as well as its clinical utility. Avanafil's faster onset and shorter duration of action has made it preferred as compared to other PDE5 inhibitors for patients with multiple comorbidities.
authors.affiliation: Tulane University School of Medicine, New Orleans, LA, USA.
authors.forename: Eric G
authors.initials: EG
authors.lastname: Katz
authors.affiliation: Department of Urology, Tan Tock Seng Hospital, Singapore.
authors.forename: Ronny Bw
authors.initials: RB
authors.lastname: Tan
authors.affiliation: Tulane University School of Medicine, New Orleans, LA, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Rittenberg
authors.affiliation: Section of Andrology, Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA.
authors.forename: Wayne J
authors.initials: WJ
authors.lastname: Hellstrom
keywords: impotence; nitric oxide; phosphodiesterase 5 inhibitors; sexual dysfunction; sildenafil